+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Daiichi Sankyo

The publisher explores Daiichi Sankyo’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Daiichi Sankyo is forecast to show strong growth through 2026 due to oncology drug Enhertu.
  • Key themes - [1] Daiichi Sankyo’s pipeline is looking very fruitful due to Enhertu [2] Enhertu is projected to reach over $2bn in sales by 2025, and will continue to grow further. It is more than capable of offsetting generic pressure from longer-listed products and increasing Daiichi Sankyo’s topline revenue [3] Daiichi Sankyo will look to use knowledge gained from Enhertu to expand its presence in the oncology field.
Model updates (30 October 2020)
  • Enhertu forecast adjusted higher due to strong launch trends in the US
  • Tarlige forecast adjusted higher
  • Lixiana forecast adjusted lower.
Model updates (31 January 2020)
  • DS-8201 launch expedited
  • Mirogabalin forecast adjusted higher due to launch progression
  • Memary forecast adjusted higher.
Model updates (31 October 2019)
  • Movantik forecast removed due to being transferred to AstraZeneca
  • MorphaBond forecast removed due to cancellation of sales agreement
  • RoxyBond forecast removed due to cancellation of sales agreement
  • DS-8201 Japan launch expedited
  • Quizartinib US and 5EU launch delayed
  • Injectafer US patent expiry added for 2027
  • Lixiana forecast adjusted higher due to sales expansion in Japan
  • Injectafer forecast adjusted higher due to raised company guidance.
Model updates (14 August 2019)
  • Savaysa/Lixiana forecast adjusted higher due to company guidance
  • Loxonin forecast adjusted lower due to generic competition
  • Olmesartan forecast adjusted higher due to company guidance
  • Nexium forecast adjusted higher due to company guidance
  • Canalia forecast adjusted higher due to strong launch
  • Vimpat forecasted adjusted higher due to launch results
  • Welchol forecast adjusted lower due to company guidance
  • Movantik forecast adjusted lower due to generic competition
  • DS-8201 forecast added.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll